These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12818261)

  • 1. Does losartan work after all?
    Blendis LM; Wong F
    Am J Gastroenterol; 2003 Jun; 98(6):1222-4. PubMed ID: 12818261
    [No Abstract]   [Full Text] [Related]  

  • 2. Discussion on randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis.
    Castaño G; Viudez P; Frider B; Sookoian S
    Gastroenterology; 2002 May; 122(5):1544-5. PubMed ID: 11984541
    [No Abstract]   [Full Text] [Related]  

  • 3. Losartan in preascitic cirrhosis.
    Castaño G; Viudez P; Sookoian S
    Am J Gastroenterol; 2004 Nov; 99(11):2282-3. PubMed ID: 15555016
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative randomized study on efficacy of losartan versus propranolol in lowering portal pressure in decompensated chronic liver disease.
    Agasti AK; Mahajan AU; Phadke AY; Nathani PJ; Sawant P
    J Dig Dis; 2013 May; 14(5):266-71. PubMed ID: 23280243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients.
    Castaño G; Viudez P; Riccitelli M; Sookoian S
    Ann Hepatol; 2003; 2(1):36-40. PubMed ID: 15094704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Portal pressure response to losartan compared with propranolol in patients with cirrhosis.
    De BK; Bandyopadhyay K; Das TK; Das D; Biswas PK; Majumdar D; Mandal SK; Ray S; Dasgupta S
    Am J Gastroenterol; 2003 Jun; 98(6):1371-6. PubMed ID: 12818283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug therapy of pulmonary and portal hypertension in liver cirrhosis].
    Vorob'ev LP; Maev IV; Andreev NG
    Klin Med (Mosk); 1991 Feb; 69(2):64-7. PubMed ID: 1875666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Medical therapy of portal hypertension due to liver cirrhosis].
    Cerini R; Sperandeo M; Varriale A; De Rosa ML; Cacciatore L
    Recenti Prog Med; 1991 Feb; 82(2):91-9. PubMed ID: 2034876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical usefulness of the angiotensin II receptor antagonist losartan in patients with portal hypertensive gastropathy.
    Wagatsuma Y; Naritaka Y; Shimakawa T; Kanako H; Keiichiro I; Shunichi S; Konno S; Katsube T; Ogawa K
    Hepatogastroenterology; 2006; 53(68):171-4. PubMed ID: 16608017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis.
    Tripathi D; Therapondos G; Lui HF; Johnston N; Webb DJ; Hayes PC
    Am J Gastroenterol; 2004 Feb; 99(2):390-4. PubMed ID: 15046234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized clinical trial of propranolol for the prevention of initial bleeding in cirrhosis with portal hypertension.
    Pagliaro L; Pasta L; D'Amico G; Filippazzo MG; Tinè F; Morabito A; Ferrari A; Marenco G; De Pretis G
    N Engl J Med; 1986 Jan; 314(4):244-5. PubMed ID: 3510389
    [No Abstract]   [Full Text] [Related]  

  • 12. A116C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension.
    Spiering W; Kroon AA; de Leeuw PW
    Am J Gastroenterol; 2005 Nov; 100(11):2601-2. PubMed ID: 16279926
    [No Abstract]   [Full Text] [Related]  

  • 13. The low incidence of bacterial infections could be a protective factor against variceal bleeding per se in hemodynamic responders to propranolol.
    Senzolo M; Cholongitas E; Marelli L; Thalheimer U; Patch D; Burroughs AK
    Am J Gastroenterol; 2006 Oct; 101(10):2436-7. PubMed ID: 17032210
    [No Abstract]   [Full Text] [Related]  

  • 14. Systematic review of HVPG measurement: statistics versus clinical applicability.
    Thalheimer U; Leandro G; Mela M; Patch D; Burroughs AK
    Gastroenterology; 2007 Mar; 132(3):1201-2; author reply 1202-4. PubMed ID: 17383448
    [No Abstract]   [Full Text] [Related]  

  • 15. [Efficacy of lisinopril and nebivolol therapy of portal hypertension and kidney dysfunction in patients with liver cirrhosis].
    Fedulenkova LV; Drozdov VN; Mikheeva OM; Petrakov AV
    Eksp Klin Gastroenterol; 2008; (5):37-41. PubMed ID: 19145915
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmacological treatment of the portal hypertension].
    Castañeda Romero B
    Rev Gastroenterol Mex; 2005 Nov; 70 Suppl 3():64-5. PubMed ID: 17471863
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of portal hypertension with nadolol in patients with liver cirrhosis.
    Cervera J; Torres-Zamora M; Gutiérrez-Carreño R; Fierro M; Schaeffer L; Landa L
    Arch Invest Med (Mex); 1983; 14(4):331-41. PubMed ID: 6678555
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect of compound Salvia pill combined with propanolol on liver fibrosis and portal hypertension].
    Liang YG; Chu XJ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2002 May; 22(5):382-3. PubMed ID: 12584844
    [No Abstract]   [Full Text] [Related]  

  • 19. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-blockers in the prevention of gastrointestinal bleeding.
    Lebrec L
    Rev Invest Clin; 1990 Jul; 42 Suppl():159-64. PubMed ID: 19256157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.